卡博普拉丁和帕克利塔塞尔与或没有贝瓦齐祖马布在老年患者中,患有晚期非小细胞肺癌
Junya Zhu1, Dhruv B Sharma, Stacy W Gray
1Center for Patient Safety, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.
JAMA
|April 19, 2012
概括
在晚期非小细胞肺癌 (NSCLC) 的老年患者中,添加贝瓦西祖马布给化疗并没有改善存活率. 这项回顾性研究发现,与 carboplatin-paclitaxel 相比,bevacizumab-carboplatin-paclitaxel 在这个人口群体中没有显著的生存优势.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 老年医学 老年医学
背景情况:
- 之前的试验表明,贝瓦齐祖马布在晚期非小细胞肺癌 (NSCLC) 中改善了生存率.
- 然而,老年患者 (≥65岁) 没有体验到这种生存益处.
研究的目的:
- 为了调查是否添加贝瓦齐祖马布加卡博普拉丁和帕克利塔塞尔化疗改善了老年NSCLC患者的存活率.
- 评估贝瓦西祖马布在老年人中晚期NSCLC的联合治疗中的疗效.
主要方法:
- 对4168名65岁以上的Medicare受益人进行了回顾性队列研究,这些受益人患有IIIB/IV期非状NSCLC.
- 使用考克斯模型和倾向性评分分析,比较贝瓦齐祖马布-碳波拉-帕克利塔塞尔与碳波拉-帕克利塔塞尔的结局.
- 从开始化疗到2009年12月31日,测量了整体生存期.
主要成果:
- 各组的中位生存时间相似:9.7个月 (含贝瓦西祖马布) 与8.9个月和8.0个月 (不含贝瓦西祖马布).
- 一年生存率是可比的:39.6%与40.1%和35.6%相比.
- 统计分析 (多变量,倾向得分) 显示,贝瓦西祖马布组合治疗没有显著的生存优势.
结论:
- 在医疗保险患者中,添加贝瓦齐祖马布加卡博普拉丁和帕克利塔克塞尔化疗并没有改善晚期NSCLC的存活率.
- 这些发现表明,贝瓦齐祖马布联合治疗对老年NSCLC患者没有生存益处.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
9.2K
11:17Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
661
相关概念视频
02:49Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K